Clinical trial
A Phase 2 Double-blind, Placebo-controlled Study to Evaluate Hemodynamic Effects of Intramuscular Injection of Human Placenta-derived Cells (Pda-002) in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease
NCT02460081 is registered in ClinicalTrials.gov with Celularity Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Double-blind, Placebo-controlled Study to Evaluate Hemodynamic Effects of Intramuscular Injection of Human Placenta-derived Cells (Pda-002) in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease
- Lead sponsor
- Celularity Incorporated
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- June 30, 2015
- Completion date
- January 6, 2016
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.